|
Barrett Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Barrett's oesophagus strongly expressed MUC5AC and MUC3 in the superficial columnar epithelium, MUC2 in the goblet cells, and MUC6 in the glands.
|
11076872 |
2000 |
|
Intestinal metaplasia
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Intestinal metaplasia is characterized by an intestinal-type pattern with MUC2 and MUC3 mRNA expression.
|
11101634 |
2000 |
|
Ductal Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MUC3 showed a progressive increase in expression in PanINs of increasing dysplasia and was also highly expressed in ductal adenocarcinoma.
|
12657964 |
2003 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
MUC17 thus inactivated NFκB to inhibit GC cell proliferation in response to pro-inflammatory cytokines.
|
31262330 |
2019 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MUC17 thus inactivated NFκB to inhibit GC cell proliferation in response to pro-inflammatory cytokines.
|
31262330 |
2019 |
|
Pancreatic intraepithelial neoplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Aberrant expression of membrane mucins MUC3 and MUC4 and of a mucin-associated carbohydrate tumor antigen Sialyl Le(x) in PanINs and adenocarcinoma further supports the progression model for pancreatic adenocarcinoma.
|
12657964 |
2003 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Aberrant expression of membrane mucins MUC3 and MUC4 and of a mucin-associated carbohydrate tumor antigen Sialyl Le(x) in PanINs and adenocarcinoma further supports the progression model for pancreatic adenocarcinoma.
|
12657964 |
2003 |
|
Adenocarcinoma of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Aberrant expression of membrane mucins MUC3 and MUC4 and of a mucin-associated carbohydrate tumor antigen Sialyl Le(x) in PanINs and adenocarcinoma further supports the progression model for pancreatic adenocarcinoma.
|
12657964 |
2003 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additional investigation of MUC3 and MUC4 in ovarian cancers may lead to new approaches for early detection and therapy.
|
9850092 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although there was no correlation of mucin expression with tumor histology, there was a significant decrease in expression of MUC3 and MUC4 with increasing cancer stage (P < 0.05).
|
9850092 |
1998 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Analysis of The Cancer Genome Atlas database indicated that mucin-17 (MUC17) was more highly expressed in gastric cancer (GC) specimens, with favourable prognosis for patients.
|
31262330 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Analysis of The Cancer Genome Atlas database indicated that mucin-17 (MUC17) was more highly expressed in gastric cancer (GC) specimens, with favourable prognosis for patients.
|
31262330 |
2019 |
|
Intestinal metaplasia
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Barrett's metaplasia was also associated with a specific MUC gene expression pattern, since the gastric apomucin mRNAs, MUC5AC and MUC6, were expressed in gastric metaplasia, and the intestinal apomucin mRNAs, MUC3, MUC4 and mostly MUC2, in intestinal metaplasia.
|
11093805 |
2000 |
|
Colon Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Both immunocytochemistry and in situ hybridization were used to identify cell types expressing the MUC2 and MUC3 mucins in the human small intestine, colon, and colon carcinoma.
|
8020672 |
1994 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Both MUC1 and MUC4 were down-regulated in gastric cancers, whereas cancer and normal tissue levels were similar for MUC3, 11, 12 and 13.
|
15375564 |
2004 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Both MUC1 and MUC4 were down-regulated in gastric cancers, whereas cancer and normal tissue levels were similar for MUC3, 11, 12 and 13.
|
15375564 |
2004 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Comparable MUC1, MUC2, and MUC3 mRNA levels were present in adenomas and normal colon, whereas mucin mRNA levels were decreased in adenocarcinomas.
|
8859775 |
1996 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Compared with corresponding normal tissue, MUC1 mRNA levels were increased in breast cancer and well-differentiated lung cancers, and MUC3 mRNA was increased in gastric adenocarcinomas.
|
7678777 |
1993 |
|
Carcinoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Eight of the genes, APC, TP53, ATM, CSMD3, LRP1B, RYR2, BIRC6, and MUC17, contained mutations in >20% of the carcinomas.
|
29575536 |
2018 |
|
Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of MUC17 is regulated by HIF1α-mediated hypoxic responses and requires a methylation-free hypoxia responsible element in pancreatic cancer.
|
22970168 |
2012 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of MUC17 is regulated by HIF1α-mediated hypoxic responses and requires a methylation-free hypoxia responsible element in pancreatic cancer.
|
22970168 |
2012 |
|
Hyperplastic Polyp
|
0.020 |
Biomarker
|
disease |
BEFREE |
Expression of MUC1, MUC2, and MUC3 core tandem repeat proteins was examined in specimens of normal mucosa (n = 20), hyperplastic polyps (n = 10), adenomatous polyps (n = 89), and invasive cancer (n = 19).
|
8859775 |
1996 |
|
Malignant tumor of colon
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Expression of MUC2 and MUC3 mRNA were both markedly decreased in poorly, moderately, and well-differentiated colon cancers but were preserved in mucinous colon cancers.
|
8813081 |
1996 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, mice treated with MUC17-CRD1-L-CRD2 protein given per rectum demonstrated accelerated healing in acetic acid and dextran sodium sulfate induced colitis in vivo.
|
20211273 |
2010 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gain- and loss-of-function assays showed that MUC17 inhibited the H. pylori-enhanced GC cell growth by preventing the translocation of H. pylori CagA into GC cells.
|
30778796 |
2019 |